SeDeM as a Tool to Validate Drug Substance Manufacturing Processes and Assess Scalability and Suitability for Direct Compression: Supplier Screening

During the development of an oral solid form of a drug substance, a thorough understanding of the critical material attributes is necessary, as the physical properties of the active pharmaceutical ingredient (API) can profoundly influence the drug product’s manufacturability, critical quality attrib...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2023-07, Vol.15 (8), p.2034
Main Authors: Figuera-Figuera, Alba, Suñé-Pou, Marc, Pérez-Lozano, Pilar, García-Montoya, Encarna, Amela-Navarro, Joaquim, Suñé-Negre, Josep M
Format: Article
Language:English
Subjects:
Cost control
critical material attribute
critical quality attribute
direct compression
Drug dosages
drug substance manufacturers
Gram-positive bacteria
Manufacturers
Manufacturing
Methicillin
Particle size
Pharmaceutical industry
Physical properties
Production processes
Reproducibility
SeDeM expert system
Staphylococcus infections
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:During the development of an oral solid form of a drug substance, a thorough understanding of the critical material attributes is necessary, as the physical properties of the active pharmaceutical ingredient (API) can profoundly influence the drug product’s manufacturability, critical quality attributes, and bioavailability. The objective of this study was to validate the manufacturing process of the drug Linezolid from three different sources at both the pilot and industrial scale and to identify differences in critical material attributes between the API manufacturers. Furthermore, the scalability factor between the pilot and industrial scale and the suitability of a process for direct compression were also evaluated. In the present study, the different sources of API were characterized by SeDeM methodology, particle size distribution, and scanning electron microscopy determinations. The statistical analysis revealed that no statistically significant differences were found for any of the parameters under study for the same API source analyzed on both scales. On the other hand, for most of the parameters evaluated, statistical differences were observed between the different sources. It was concluded that SeDeM was able to successfully validate the API manufacturing process, assess scalability, and distinguish between sources. Therefore, it could be highly valuable in the formulation phase to select the best API source.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics15082034